Peptide Therapies

---

Growth Hormone Releasing Hormone (GHRH) Analog;  Sermorelin is a synthetic compound classified as a growth hormone-releasing peptide, specifically designed to stimulate the release of growth hormone within the body.  traditionally used to diagnose and treat low level Human Growth Hormone (hGH) across various age groups. It causes the release of hGH from the pituitary gland, harnessing the effects of naturally secreted hGH. Unlike long-term exogenous hGH therapy, Sermorelin is not associated with

Growth Hormone Releasing Hormone (GHRH) Analog ;  Ipamorelin is a synthetic compound classified as a growth hormone-releasing peptide, specifically designed to stimulate the release of growth hormone within the body. This process encourages systemic growth across various tissues and organs, including muscle, bone, and vasculature. What sets Ipamorelin apart from many other growth hormone-releasing peptides is its distinctive characteristic of not triggering the body's natural stress response. Th

Growth Hormone Releasing Hormone (GHRH) Analog;  CJC-1295 is a synthetic compound classified as a growth hormone secretagogue (GHS), specifically designed to stimulate the release of growth hormone within the body. By binding to pituitary receptors, CJC-1295 exerts its effects by stimulating the release of plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Mechanism similar to Sermorelin but has longer duration of action due to delayed clearance from the body.

BPC-157 is derived from the natural Body Protection Compound found in human gastric juices. Primarily recognized for its healing and restorative properties, this peptide facilitates angiogenesis (the formation of new blood vessels) by potentially upregulating growth factors, modulating nitric oxide (NO) synthesis, and regulating collagen production. As a result, it expedites recovery in conditions such as tendon injuries and burns, while also providing neuroprotection and supporting increased mu

TB-500 is the synthetic version of the naturally-occurring Thymosin Beta-4 with a longer half-life. It operates in cell repair and regeneration by enhancing the expression of actin, a pivotal protein in cell structure and movement, and concurrently inhibiting actin polymerization. Its main mechanism involves sequestering actin, essentially anchoring actin in specific locations. Additionally, there is evidence suggesting its ability to stimulate angiogenesis, possibly through modulation of the N

1) Rapid Tissue Repair for Injuries and Recovery

2) Improves Cardiovascular Health

3) Treats Gastrointestinal Conditions

4) Boosts Immune System

These benefits are synergistically amplified in combination therapy for various conditions

The spectrum of conditions KPV has been employed to treat is broad, ranging from inflammatory skin and bowel diseases to fibrosis, allergic reactions, inflammation of the eyes, arthritis, and beyond. Its mechanism of action involves interacting with inflammatory signaling molecules, thereby modulating key aspects of the inflammatory cell migration. Moreover, its antimicrobial properties, particularly against S. aureus and C. albicans, augment its utility in combating infections.

o Reducing inflammation

o Boosting Immune function

o Aiding in the recovery of Injuries

Met-Enkephalin is a synthetic molecule resembling the naturally occurring opioid peptide metenkephalin.  Its mechanism allows for optimal pain control while healing and helping to promote tissue repair.

o Pain relief:  As an opioid peptide, it binds to receptors in the brain and spinal cord to alleviate pain.

o Promotes Tissue Repair and Regeneration: It is beneficial for healing processes.

o Improves Intestinal Motility: Improves gastrointestinal fu

o Neurocognitive functions: particularly in 

Glucagon-like peptide-1 receptor agonist (GLP-1 RA); originally a type 2 diabetes (DM2) medication now popularly utilized for weight loss. It exerts its hypoglycemic effects by mimicking GLP-1, stimulating the pancreatic beta cells responsible for insulin production and release and inhibiting glucagon production. Overall, it decreases appetite and slows gastric emptying. In 2017, FDA approved its use for weight loss.

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and Gastric Inhibitory Polypeptide (GIP) ;  Tirzepatide is a synthetic peptide, acting as a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist.  Functionally, tirzepatide stimulates insulin release from the pancreas, resulting in a reduction of hyperglycemia.  It has shown to produce greater reductions of hyperglycemia versus that of GLP-1 RA's alone.

AOD 9604 is a lipolytic peptide with a sequence of amino acids mimicking the C-terminal domain of hGH from 176-191 and is responsible . Originally it was developed as an anti-obesity medication with properties stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat synthesis) without impacting insulin levels. These processes result in weight loss and reduction of body fat.  Other potential benefits: muscle growth, bone strengthening, improved skin elasticity, and anti-inflammation.

There are so many more peptides available from orals to injectable that are beneficial to optimizing fat metabolism. A thorough evaluation by the physician will be conducted to determine which regimen best suits the individual.